Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

UK Government and Oxford Nanopore Forge Partnership to Advance Genomics in the NHS, Enhancing Patient Care and Biosecurity

HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

Home
/
update
/
details

Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

NextEdge Admin

06 Nov 2024

3 min 36 sec

Karolinska Institutet,AI models,prostate cancer

Inify Laboratories, an innovative provider of pathology-based cancer diagnostics, is pleased to announce a strategic partnership with the ProMort research team at Karolinska Institutet. This collaboration aims to revolutionize prostate cancer diagnostics by enhancing diagnostic precision through advanced AI-powered image analysis.

“When our ProMort team began discussions with Inify, it became clear just how powerful their technology and organizational capabilities are. This partnership holds great potential to advance the vital work of identifying markers to accurately assess malignancy levels in prostate cancer, while ensuring high and consistent quality. I am thrilled about this collaboration and look forward to seeing exceptional AI models paired with exceptional talent,” says Olof Akre, Professor of Oncological Surgery at the Department of Molecular Medicine and Surgery at Karolinska Institutet.

The ProMort program is a multidisciplinary, international research initiative focused on creating high-performance prognostic tools for prostate cancer that can be applied in clinical settings, helping to tailor the best treatment to each patient. The program’s goals include:

- Identifying molecular markers associated with prostate cancer mortality using tumor tissue from diagnostic biopsies.
- Discovering new histopathological features linked to prostate cancer mortality through both traditional pathology and artificial intelligence (AI).
- Enhancing prognostic capabilities by integrating clinical variables with findings from the previous two aims into an innovative prognostic tool.

Throughout this project, Inify’s AI platform will be used to annotate various prostate cancer growth patterns, with a focus on cribriform structures, perineural invasion, and reactive stroma. These annotations will help train AI models capable of accurately identifying and defining these structures, thus accelerating the diagnostic process and creating a more consistent, streamlined result with reduced variability between observers.

“The project aligns perfectly with our vision of advancing precision diagnostics in prostate cancer. We’re excited to collaborate with such a distinguished research group at Karolinska Institutet,” says Fredrik Palm, CEO of Inify Laboratories.

Arto Järvinen, CTO of Inify Laboratories, adds, “Patient outcomes represent the ultimate ground truth for training diagnostic AI. This research project offers a rare opportunity to uncover previously undetected or unverified correlations between histopathological features and patient outcomes. We’re proud to support this critical research, which closely aligns with Inify’s own strategic priorities.”